RE-BVS – Piemonte Repository

Sfoglia per AUTORE
VERGOTE I
Collezione AO Ordine Mauriziano

Items : 9

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. in Gynecologic oncology / Gynecol Oncol. 2024 Jun;185:202-211. doi: 10.1016/j.ygyno.2024.05.016. Epub 2024 Jun 3.

2024
AO Ordine Mauriziano

Makker V; Perez-Fidalgo JA; Valabrega G; Hamilton E; Van Gorp T; Sehouli J; Reginá?ová K; Richardson DL; Perri T; Oza AM; Miller DS; Alía EMG; De Giorgi U; Henry S; Spitz DL; Wimberger P; Bedna?íková M; Chon HS; Martínez-Garcia J; Pisano C; Berek JS; Romero I; Scambia G; Fariñas-Madrid L; Buscema J; Schochter F; Li K; Kalyanapu P; Walker CJ; et alii...

Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. in Gynecologic oncology / Gynecol Oncol. 2023 Jul;174:80-88. doi: 10.1016/j.ygyno.2023.04.028. Epub 2023 May 9.

2023
AO Ordine Mauriziano

Vergote I; Van Nieuwenhuysen E; Casado A; Laenen A; Lorusso D; Braicu EI; Guerra-Alia E; Zola P; Wimberger P; Debruyne PR; Falcó E; Ferrero A; Muallem MZ; Kerger J; García-Martinez E; Pignata S; Sehouli J; Van Gorp T; Gennigens C; Rubio MJ;

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5.

2023
AO Ordine Mauriziano

Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; et alii...

Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer. in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society / Int J Gynecol Cancer. 2016 Oct;26(8):1521-4. doi: 10.1097/IGC.0000000000000788.

2016
AO Ordine Mauriziano

Panuccio E; Leunen K; Van Nieuwenhuysen E; Neven P; Lambrechts S; Vergote I;

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. in Targeted oncology / Target Oncol. 2016 Jun;11(3):429. doi: 10.1007/s11523-016-0433-x.

2016
AO Ordine Mauriziano

Despierre E; Vergote I; Anderson R; Coens C; Katsaros D; Hirsch FR; Boeckx B; Varella-Garcia M; Ferrero A; Ray-Coquard I; Green JA; Steer C; Berns EM; Casado A; Lambrechts D; Jimeno A;

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. in Gynecologic oncology / Gynecol Oncol. 2015 Jan;136(1):18-24. doi: 10.1016/j.ygyno.2014.09.017. Epub 2014 Oct 2.

2015
AO Ordine Mauriziano

Lee CK; Lord S; Grunewald T; Gebski V; Hardy-Bessard AC; Sehouli J; Woie K; Heywood M; Schauer C; Vergote I; Scambia G; Ferrero A; Harter P; Pujade-Lauraine E; Friedlander M;

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2015 Feb;51(3):352-8. doi: 10.1016/j.ejca.2014.11.017. Epub 2014 Dec 17.

2015
AO Ordine Mauriziano

Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A;

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. in Targeted oncology / Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6.

2015
AO Ordine Mauriziano

Despierre E; Vergote I; Anderson R; Coens C; Katsaros D; Hirsch FR; Boeckx B; Varella-Garcia M; Ferrero A; Ray-Coquard I; Berns EM; Casado A; Lambrechts D; Jimeno A;

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669. Epub 2013 Dec 23.

2014
AO Ordine Mauriziano

Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E;